Lilly has licensed from Incyte worldwide rights to an oral JAK1/JAK2 inhibitor in a Phase II dose-ranging study for rheumatoid arthritis. Under the development and commercialisation pact, Lilly also has rights to certain follow-on compounds.
Lilly will pay $90 million up front and up to $665 million in milestones, as well as tiered double-digit royalties...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
